Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | RECQL | P46063 | 3/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD4 | P21917 | 2/20 | 0.58 |
| ▸ | DRD5 | P21918 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.58 |
| ▸ | APEX1 | P27695 | 2/20 | 0.58 |
| ▸ | THPO | P40225 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopamine SCHEMBL28310234 | 1.00 | KDM4E (0.58) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Dopamine SCHEMBL28839736 | 0.90 | KDM4E (0.57) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Levodopa SCHEMBL23069544 | 0.86 | SLC7A5 (0.79) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Dopamine SCHEMBL28469370 | 0.86 | KDM4E (0.62) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Norepinephrine SCHEMBL6440372 | 0.86 | TDP1 (0.52) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Levodopa SCHEMBL5494243 | 0.84 | SLC7A5 (0.82) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Levodopa SCHEMBL5494247 | 0.84 | SLC7A5 (0.82) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Levodopa SCHEMBL1491628 | 0.84 | SLC7A5 (0.82) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| Levodopa SCHEMBL1491625 | 0.84 | SLC7A5 (0.82) | KDM4ETDP1RECQLHIF1AHSD17B10 | |
| SCHEMBL5287328 | 0.84 | KDM4E (0.70) | KDM4ETDP1RECQLHIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | COGMOTIV FLEXCO (AT) | 2026-04-28 | — | — | US | disclosed |
| EP-4707410-A2 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | California Institute of Technology (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250375486-A1 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | CALIFORNIA INST OF TECHN (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250197509-A1 | ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2025-06-19 | — | — | US | disclosed |
| US-12329786-B2 | Regulate gut microbiota to treat neurodegenerative disorders | CALIFORNIA INSITUTE OF TECHNOLOGY (US) | 2025-06-17 | — | — | US | disclosed |
| US-12221484-B2 | Anti-NMDA receptor antibodies and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240000862-A1 | REGULATE GUT MICROBIOTA TO TREAT NEURODEGENERATIVE DISORDERS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-01-04 | — | — | US | disclosed |
| US-11707493-B2 | Regulate gut microbiota to treat neurodegenerative disorders | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220324821-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES | COGMOTIV FLEXCO (AT) | 2022-10-13 | — | — | US | disclosed |
| CN-114401948-A | Thiazole and diphenyl substituted sulfoxides for improving cognitive function and combating substance addiction | 红牛有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20140235576-A1 | PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS IGLUR ANTAGONISTS | KOBENHAVNS UNIVERSITET (DK) | 2014-08-21 | — | — | US | disclosed |
| US-8282559-B2 | Method for inducing and monitoring long-term potentiation and long-term depression using transcranial doppler ultrasound device in head-down bed rest | NJEMANZE PHILIP CHIDI (NG) | 2012-10-09 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010135643-A1 | FORMATION OF ACCUMBENS GLUR2-LACKING AMPA RECEPTORS MEDIATES INCUBATION OF COCAINE CRAVING | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010088408-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100048722-A1 | FORMATION OF ACCUMBENS GluR2-LACKING AMPA RECEPTORS MEDIATES INCUBATION OF COCAINE CRAVING | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2010-02-25 | — | — | US | disclosed |
| US-20080221452-A1 | Method for inducing and monitoring long-term potentiation and long-term depression using transcranial doppler ultrasound device in head-down bed rest | NJEMANZE PHILIP CHIDI | 2008-09-11 | — | — | US | disclosed |
| WO-2004092417-A2 | MOLECULAR CORRELATES OF COCAINE ADDICTION AND METHODS FOR THEIR USE | EMORY UNIVERSITY (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612374-B2 | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances | CHAT, PNMT, CHRM5 | KDM4E 504/4885TDP1 120/4885RECQL 3807/4885 |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | KDM4E 3493/4885TDP1 1865/4885RECQL 4342/4885 |
| US-20110319416-A1 | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | KDM4E 2771/4885TDP1 2079/4885RECQL 3879/4885 |
| US-20140235576-A1 | PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES AS IGLUR ANTAGONISTS | GRIK2, GABRE, GRIK5 | KDM4E 3591/4885TDP1 1556/4885RECQL 4737/4885 |
| US-20220324821-A1 | THIAZOLE AND DIPHENYL SUBSTITUTED SULFOXIDES FOR USE IN IMPROVING COGNITION FUNCTIONS AND AGAINST ADDICTIONS TO SUBSTANCES | COMT, TST, PNMT | KDM4E 376/4885TDP1 122/4885RECQL 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.